Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dostarlimab

dostarlimab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dostarlimab

8 trials tracked of dostarlimab.

8Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 6 Phase 1 2
  1. Phase 2 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 Completed
  2. Phase 2 Niraparib + Dostarlimab + RT in Pancreatic Cancer Completed
  3. Phase 2 Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC Completed
  4. Phase 2 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) Completed
  5. Phase 2 Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer Completed
  6. Phase 2 Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Completed
Show 2 more trials
  1. Phase 1 Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors Completed
  2. Phase 1 Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MMR status-guided immunotherapy provides favorable cost-effectiveness and quality-adjusted survival in dMMR/MSI-H endometrial cancer
Allergy & Immunology Sys. Review
MMR status-guided immunotherapy provides favorable cost-effectiveness and quality-adjusted survival in dMMR/MSI-H endometrial cancer MMR Testing Helps Identify High Value Treatment for Endometrial Cancer
This mini review examines the economic value of mismatch repair (MMR) status-guided immunotherapy for advanced and recurrent endometrial can…
Testing for mismatch repair status helps doctors identify which patients with advanced endometrial cancer may benefit most from specific imm…
Frontiers Sep 10, 2026
Dostarlimab and Niraparib Combination Improves Progression Free Survival in Advanced Endometrial Cancer
Oncology RCT
Dostarlimab and Niraparib Combination Improves Progression Free Survival in Advanced Endometrial Cancer Adding Niraparib to Dostarlimab Delays Endometrial Cancer Worsening
A Phase 3 trial shows that adding niraparib to dostarlimab maintenance significantly extends progression-free survival for patients with adv…
A phase 3 trial found that adding niraparib to dostarlimab after chemo slowed cancer growth in advanced endometrial cancer, but did not exte…
Aug 10, 2026
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
Oncology Meta-analysis
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer Mapping the Research Landscape of Immune Therapy for Endometrial Cancer
This systematic review uses a bibliometric analysis to map the landscape of immune checkpoint inhibitor research in endometrial cancer. The …
A large-scale analysis maps out how researchers worldwide are studying immune checkpoint inhibitors to treat endometrial cancer.
Frontiers Jun 8, 2026